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Abstract
Background The literature on the prognostic relevance of signet-ring cell (SRC) histology in gastric cancer (GC) is contro-
versial which is most likely related to inconsistent SRC classification based on haematoxylin–eosin staining. We hypothesised 
that mucin stains can consistently identify SRC-GC and predict GC patient outcome.
Methods We performed a comprehensive literature review on mucin stains in SRC-GC and characterised the mucin expres-
sion in 851 Caucasian GC and 410 Asian GC using Alcian Blue (AB)-Periodic Acid-Schiff (PAS), MUC2 (intestinal-type 
mucin), and MUC5AC (gastric-type mucin). The relationship between mucin expression and histological phenotype [poorly 
cohesive (PC) including proportion of SRCs, non-poorly cohesive (non-PC), or mucinous (MC)], clinicopathological vari-
ables, and patient outcome was analysed.
Results Depending on mucin expression and cut-offs, the positivity rates of SRC-GC reported in the literature varied from 
6 to 100%. Patients with MUC2 positive SRC-GC or SRC-GC with (gastro)intestinal phenotype had poorest outcome.
In our cohort study, PC with ≥ 10% SRCs expressed more frequently MUC2, MUC5AC, and ABPAS (p < 0.001, p = 0.004 
and p < 0.001, respectively). Caucasians with AB positive GC or combined ABPAS-MUC2 positive and MUC5AC negative 
had poorest outcome (all p = 0.002). This association was not seen in Asian patients.
Conclusions This is the first study to suggest that mucin stains do not help to differentiate between SRC-GC and non-SRC-
GC. However, mucin stains appear to be able to identify GC patients with different outcome. To our surprise, the relationship 
between outcome and mucin expression seems to differ between Caucasian and Asian GC patients which warrants further 
investigations.
Keywords Gastric cancer · Signet-ring cells · Mucin · Histological phenotype · Survival
Introduction
Gastric cancer (GC) is a heterogenous disease with respect 
to epidemiology, morphology, and clinical behaviour. 
Despite declining incidence, GC remains one of the major 
causes of cancer-related death worldwide [1]. The incidence 
of poorly cohesive GC, including signet-ring cell (SRC) can-
cer, appears to be rising in the Western World [2, 3]. Several 
studies investigating the prognostic relevance of SRC histol-
ogy reported conflicting results [4–8]. In some studies, SRC 
histology was associated with poor outcome, which was not 
confirmed in other studies [4–10]. Furthermore, it has been 
suggested that the relationship between SRC histology and 
outcome may depend on the disease stage in GC patients 
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[11–17]. The clinical utility of the proportion of SRCs to 
predict response to preoperative chemo(radio)therapy in GC 
patients remains a matter of debate [18–24].
A recent expert panel hypothesised that these inconclu-
sive results could be related to inconsistencies in the his-
tological classification of SRC-GC [25]. Whilst SRC-GC 
have always been typed as diffuse-type cancers in the Lauren 
classification [26], the WHO definition of SRC-GC changed 
several times between the 1st edition in 1977 [27] and the 
4th edition in 2010 [28]. Up to the 4th edition [27, 29, 30], 
when SRC-GC became a subcategory of poorly cohesive 
GC, SRC-GC was classified as a separate specific subtype 
of GC. Furthermore, the definition of the extent of SRCs 
to qualify as SRC-GC changed over the years from ‘pre-
dominant’, to more than 50% SRCs in the 2nd edition WHO 
[29] and back to “predominantly” or “exclusively” in the 4th 
and 5th editions WHO [28, 31]. In an attempt to achieve a 
more consistent classification of SRC-GC, a multidiscipli-
nary expert panel recently proposed specific cut-off values 
for the percentage of SRCs to distinguish bona-fide SRC-
GC (more than 90% SRCs) from poorly cohesive GC with 
SRC component (between 10 and 90% SRCs) and poorly 
cohesive GC not otherwise specified (less than 10% SRCs) 
[25]. However, what remains particularly challenging is the 
unequivocal definition of what constitutes a SRC based on 
routine histology as exemplified by the 5 different types of 
SRCs described in the 3rd edition WHO [30]. Therefore, 
there remains an urgent clinical need to identify a specific 
biomarker for SRCs to standardise SRC-GC classification 
and establish the clinical importance of SRC-GC.
We hypothesised that (1) SRC containing gastric cancers 
have a different mucin expression compared to non-SRC 
gastric cancers, and (2) there is an association between SRC 
mucin expression, clinicopathological variables, and patient 
outcome.
The present study consists of two parts: (1) a comprehen-
sive literature search to establish the frequency and clinical 
importance of mucin stains in SRC containing GC, and (2) 
a large cohort study in Asian and Caucasian GC where the 
histological phenotype was classified according to recently 
published consensus guidelines and the expression of sev-
eral different mucin stains and its relationship to clinico-
pathological variables, patient outcome, and ethnicity was 
investigated.
Materials and methods
Literature review
A comprehensive literature search was conducted in the 
PubMed database including all publications up to October 
1st, 2018 using synonyms and MESH terms for ‘gastric’ 
and ‘signet-ring cell cancer’ (see Online Resource 1). The 
title and abstract of resulting articles were screened based 
on the following inclusion criteria: the abstract or title men-
tioned SRC-GC, and results from histochemical or immu-
nohistochemical mucin stains were reported separately for 
SRC-GC (see Fig. 1). If a study provided both, data from an 
SRC-GC and non-SRC-GC cohorts, only the SRC-GC data 
were extracted and analysed. We excluded studies reporting 
results from less than 10 SRC-GC, referring to hereditary 
diffuse GC, metastases with SRCs or unknown primary 
tumour, cell culture-based studies, animal studies, diagno-
ses based on cytology, and letters to editors containing no 
additional information. We also excluded studies where we 
were unable to retrieve the full-text version of the article, 
articles written in languages other than English or Japanese, 
and articles reporting only on gastro-oesophageal junction 
adenocarcinomas.
From the included studies, we extracted information 
about the definition of SRC-GC, classification system used, 
frequencies of positivity for histochemical and immunohis-
tochemical mucin stains, differences in mucin expression 
between SRC-GC and relationship between mucin expres-
sion in SRC-GC, patient outcome, and other clinicopatho-
logical factors.
Gastric cancer cohort study
Patients
We included 851 Caucasian patients from Leeds Teach-
ing Hospitals NHS Trust (LTHT), Leeds, UK, and 410 
Asian patients from the Kanagawa Cancer Center Hospital 
(KCCH), Yokohama, Japan, diagnosed with adenocarci-
noma of the stomach or gastro-oesophageal junction. All 
patients underwent potentially curative gastrectomy or gas-
tro-oesophagectomy with lymph node dissection. 76 patients 
had neoadjuvant chemotherapy. Clinical variables (age, sex, 
treatment, overall and 5-year survival, and mortality status) 
and histopathological variables [(y)pT, (y)pN, grade of dif-
ferentiation, and tumour location] were retrieved from hos-
pital records and pathology reports. The study protocol was 
approved by the relevant local ethics committees.
Tissue microarrays (TMAs) had been previously con-
structed from the resection specimen [32]. Three 0.7 mm 
cores where sampled from each LTHT GC and two 1.2 mm 
cores from each KCCH GC. The cores were taken from areas 
with the highest tumour density in both cohorts. Four micron 
thick sections were cut and stained with haematoxylin–eosin 
(H&E) using a standard protocol and subjected to histo-
chemical stains and immunohistochemistry as described 
below. Slides were scanned at × 40 magnification using an 
Aperio XT Scanner (Aperio Technologies, Vista, CA, USA) 
at the University of Leeds slide scanning facility and viewed 
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using Aperio ImageScope (version 12.3.2.8013). Scoring 
of the immunohistochemical stains was performed indepen-
dently by two observers (D.L. and K.K.), and discrepant 
scores were reviewed and discussed jointly until agreement 
was reached.
Histological classification
The H&E stain was used to classify GC based on 5th edition 
WHO Classification of Tumours of the Digestive System 
[31] in combination with the recently published consen-
sus [25]. A poorly cohesive GC was defined as a cancer 
composed of isolated neoplastic cells or small aggregates 
of neoplastic cells [31]. To be classified as a mucinous GC, 
more than 50% of tumour area had to be occupied by pools 
of extracellular mucin [31]. GC not fulfilling the criteria for 
either poorly cohesive or mucinous GC were classified as 
non-poorly cohesive GC.
A classical SRC was defined as a cell with ample opti-
cally clear cytoplasmic mucin on H&E stain and eccentri-
cally placed nucleus. To compare the mucin expression 
characteristics of SRCs in poorly cohesive GCs with looka-
likes SRCs in non-poorly cohesive and mucinous GCs, we 
decided to quantify the proportion of SRCs in all histo-
logical subtypes based on the H&E appearance in 4 cat-
egories: < 10% SRCs, ≥ 10–50% SRCs, ≥ 50–90% SRCs, 
and ≥ 90% SRCs. This classification was performed blinded 
to (immuno)histochemical expression results or clinico-
pathological information.
Mucin histochemistry and immunohistochemistry
All GCs were stained for Alcian Blue (AB)-Periodic Acid-
Schiff (PAS) combined with pan-cytokeratin (CK-ABPAS), 
MUC2, and MUC5AC. We chose ABPAS to differentiate 
between acidic and neutral mucin. ABPAS stain was com-
bined with immunohistochemistry for pan-cytokeratin to 
distinguish between mucin within epithelial cells, mucin 
within non-epithelial cells such as macrophages and extra-
cellular mucin. We chose MUC2 as intestinal-type mucin 
stain and MUC5AC as gastric-type mucin stain, since these 
Fig. 1  Flowchart of included 
papers in literature study. SRC 
signet-ring cell; GC gastric 
cancer
Search Pubmed:  
‘gastric’ AND ‘signet-ring cell carcinoma’
1696 papers
1419 papers
Not fullfilling in- and 
exclusion criteria
277 papers
84 papers
193 papers 
- <10 SRC-GC (181) 
- No separate data on SRC-
GC (11) 
- Hereditary carcinoma (1)
35 papers
Mucin stains in 
SRC-GC
49 papers
- Not reporng on mucin 
stains
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stains were most frequently used in studies in the literature 
[33–40].
After deparaffinisation in xylene and rehydration fol-
lowing a standard protocol, the pan-cytokeratin stain was 
performed first (see below) followed by the ABPAS stain. 
We used 1% AB solution (pH 2.5), 1% periodic acid solu-
tion, and Schiff’s solution following our routine laboratory 
protocol. Slides were dehydrated, coverslipped, and scanned.
For all antibodies, antigen retrieval was performed in a 
microwavable pressure cooker using 10 mM citrate buffer, 
pH 6.0, and full pressure for 5 min. Hydrogen peroxide and 
egg white solution were used to block endogenous per-
oxidase activity and endogenous biotin, respectively. The 
sections were incubated with antibodies against MUC2 
(dilution 1:100, clone CCP58; Agilent/Dako), MUC5AC 
(dilution 1:100, clone CLH2; Agilent/Dako), and pan-
cytokeratin (dilution 1:200, clone AE1/AE3; Agilent/Dako) 
for 1 h at 37 °C. Dako Real streptavidin–biotin detection kit 
was used as detection system and 3,3′-Diaminobenzidine 
(DAB) as chromogen (Dako) according to the instructions of 
the manufacturer. Slides were counterstained with Mayer’s 
haematoxylin, dehydrated, coverslipped, and scanned.
Scoring of mucin stains
For all three stains (MUC2, MUC5AC, and ABPAS), a core 
with ≥ 10% stained tumour cells was classified as positive, 
irrespective of expression intensity. For this scoring, all 
tumour cells were considered irrespective of their morphol-
ogy (signet-ring cell or not). If one of the cores of a case was 
classified as being positive, the whole case was classified 
as positive.
ABPAS-positive cores were initially subdivided into 5 
categories: (1) AB positive; (2) PAS positive; (3) mixed pos-
itivity—same cells AB and PAS positive; (4) mixed positiv-
ity—different cells AB and PAS positive; (5) combination 
of categories 3 and 4. A case was classified as positive for 
both ABPAS, if AB and PAS positivity was seen in the same 
core (category 3–5) or if one core was AB positive (category 
1) and another core was PAS positive (category 2). As the 
number of cases in certain ABPAS subcategories was very 
small, we subsequently combined groups (see Table 1).
Furthermore, we created additional variables by combin-
ing the results of the different mucin stains (ABPAS, MUC2, 
and MUC5AC) (see Online Resource 2).
Statistical analyses
Data were analysed using SPSS Statistics for Windows ver-
sion 25.0 (IBM, Armonk, NY, USA). Patient characteris-
tics, histological tumour types, and mucin expression were 
compared between the LTHT and the KCCH cohorts using 
the Mann–Whitney U test for continuous variables and the 
Pearson Chi-square test for categorical variables. For the 
analysis of the association between histological phenotype 
and mucin expression, results from both cohorts (LTHT 
and KCCH) were combined. Associations between mucin 
expression and clinicopathological variables were assessed 
using the Kruskal–Wallis test. For survival analyses, indi-
vidual mucin expression and combinations of mucin expres-
sions (see Online Resource 2) were used. Kaplan–Meier 
survival analysis and log-rank test were used to compare 
5-year and overall survival between patients with different 
histological tumour types or different mucin expression. 
16 LTHT patients and 60 KCCH patients underwent neo-
adjuvant chemotherapy, respectively. To determine whether 
neoadjuvant treatment influenced the results, all analyses 
were repeated excluding these 76 patients. As all associa-
tions remained the same, we report here results based on the 
whole cohort. p values < 0.05 were considered statistically 
significant.
Results
Literature review of mucin stains in gastric 
signet‑ring cell cancers
The literature search in PubMed resulted in only 35 studies 
published over a period of 40 years (between 1977 and 2017) 
(see Fig. 1). The median number of SRC-GC patients per 
study was 37 (range 11–317), and the percentage of SRC-GC 
within individual studies ranged from 7 to 100%. The major-
ity of studies (n = 25, 71%) originated from Asia.
Definition of gastric signet‑ring cell cancers 
and classification system used
The definition of SRCs and the classification system used 
varied between studies (see Tables 2 and 3). Some authors 
provided a very detailed description mentioning intracel-
lular accumulation of PAS, AB, and/or mucicarmine posi-
tive mucin [41–44] together with an eccentric nucleus as 
defining factors [44] or described ‘classical SRCs’ next to 
small SRCs with deep eosinophilic cytoplasm and a round 
larger hyperchromatic nucleus [45]. Other authors neither 
described the definition of SRC nor mentioned the classifica-
tion system used. Some studies used cut-off values to define 
SRC-GC, either in concordance with the 2nd and 3rd edi-
tions WHO classification (50% rule) [35, 36, 38, 46–51] or 
using the 4th edition WHO classification [28] (predominant 
or exclusive rule without specific percentage) [41, 42]. One 
of the studies used a cut-off value of 90% to define a GC as 
SRC-GC [53].
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Gastric signet‑ring cell cancer and histochemical mucin 
stains
We identified 12 studies reporting on histochemical mucin 
stains in SRC-GC published between 1977 and 2013. The 
median number of included SRC-GC cases was 28 (range 
11–102).
Different studies used single stain or combination of 
stains to classify SRC-GC (see Table 4).
Three studies combined morphological features and his-
tochemical mucin stains to classify SRC-GC into several 
subtypes. Kubota et  al. [53] used AB, AB-PAS, and 
LNAase stains to classify 64 SRC-GC as type A (imma-
ture: PAS weak positive, AB negative, LNAase positive, 
small cell size, and high nuclear/cytoplasmic ratio), type 
B (intermediate: stronger PAS positivity, AB negative or 
weak positive, LNAase positive, and smaller nuclear/cyto-
plasmic ratio) or type C (mature: PAS strong positive, AB 
positive, and eccentric nucleus). The C-type was further 
divided in C1 and C2 subtypes with the C1 subtype show-
ing weaker AB positivity combined with LNAase positiv-
ity and the C2 subtype showing stronger AB positivity 
Table 1  Descriptive statistics of 
the two cohorts
n number of cases, SRC signet-ring cell, PC poorly cohesive cancer, non-PC non-poorly cohesive cancer, 
MC mucinous cancer, SD standard deviation
Overall (n = 1261) Caucasian (n = 851) Asian (n = 410) p value
n % n % n %
Gender (male) 852 68 557 66 295 72 0.026*
Mean age (years) 66.6 (SD 11.0) 68.2 (SD 10.8) 63.3 (SD 10.7) < 0.001*
T stage  < 0.001*
 T1 131 11 96 12 35 9
 T2 146 12 84 11 62 15
 T3 307 26 252 33 55 13
 T4 600 51 343 44 257 63
N stage < 0.001*
 N0 359 29 275 32 84 21
 N1 264 21 177 21 87 22
 N2 296 24 194 23 102 25
 N3 340 27 204 24 136 33
Classification 0.641
 PC < 10% SRCs 192 15 129 15 63 15
 PC > 10% SRCs 67 5 46 5 21 5
 Non-PC < 10% SRCs 905 72 608 71 297 72
 Non-PC > 10% SRCs 38 3 23 3 15 4
 MC < 10% SRCs 14 1 9 1 5 1
 MC > 10% SRCs 27 2 22 3 5 1
 Non-informative 18 1 14 2 4 1
Mucins
 MUC2 0.043*
  Negative 1050 83 698 82 352 86
  Positive 173 14 129 15 44 11
 MUC5AC < 0.001*
  Negative 844 67 544 64 300 73
  Positive 387 31 289 34 98 24
 ABPAS 0.037*
  Negative 974 77 674 79 300 73
  Positive 255 20 159 19 96 23
*AB positive 62 5 47 6 15 4
*PAS positive 37 3 23 3 14 3
*Mixed, same cells 7 0.6 2 0.2 5 1
*Mixed, different cells 4 0.3 4 0.5 0 0
*Mixed, both expressions 145 12 83 10 62 15
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combined with negative LNAase expression. Akamatsu 
et al. [54] used five histochemical stains (AB-PAS, HID-
AB, GOS, PA-SB-PH-PAS, and PCS) to classify 31 SRC-
GC into 6 subtypes (1) surface mucous cell-type; (2) 
mucous neck cell-pyloric cell-type; (3) goblet cell (small 
intestine)-type; (4) goblet cell (large intestine)-type; (5) 
microcyst-type and (6) unclassified. Although different 
SRC sub types could be present in the same tumour, types 
1, 2, 3, and 4 were observed most frequently as the domi-
nant cell type. In addition, the authors described the pres-
ence of the so-called intramucosal laminated structures 
(ILS) in SRC cancer distinguishing three types: complete 
(upper, middle, and lower layers of the mucosa), incom-
plete (upper and middle layers), and inverted (middle 
and lower layer) based on morphology and histochemi-
cal mucin expression. Tatematsu [55, 56] combined his-
tochemical stains for PCS, GOS, and sialidase GOS with 
immunohistochemical stains for pepsinogen I and II to 
classify 127 SRC-GC as gastric phenotype, intestinal phe-
notype, or mixed gastrointestinal phenotype. The gastric 
phenotype was the most prevalent subtype (in both studies 
approximately 74%).
However, the above mentioned detailed histomorpho-
logical subclassifications of SRC-GC have not been vali-
dated in any subsequent studies and the relationship with 
clinical variables has only been investigated by Akamatsu 
[54] who did not find any associations.
Table 3  Results from studies in the literature reporting on mucin phenotypes based on immunohistochemical mucin stains
n number of cases, % percentage of all cases, G gastric phenotype, I intestinal phenotype, GI gastrointestinal phenotype, U unclassified, NA not 
applicable, NR not reported, SRC signet-ring cell, GC gastric cancer, WHO World Health Organisation, JGCA Japanese Gastric Cancer Associa-
tion
a Percentages rounded up
b 2nd edition WHO
c 3rd edition WHO
Author Year Number 
SRC-GC
Descrip-
tion SRC-
GC
Classification 
tumour type 
used
Mucin phenotypes (% of total SRC-GCa) Relationship 
with survival
Comparison 
with other 
tumour types
n % G I GI/mixed U Yes/No
Bamba M 2001 54 100 Yes JGCA 28 2 69 NA Yes No
Tsukashita S 2003 17 17 No NR 77 0 0 23 NR Yes
Aihara R 2004 69 100 Yes WHOb, JGCA 60 0 41 0 Yes No
Aihara R 2005 69 54 Yes WHOb 47 2 46 5 Yes Yes
Ohkura Y 2005 79 28 No No SRC: 81; 
mixed: 35
SRC: 2; 
mixed: 15
SRC: 16; 
mixed: 50
0 NR No
Tian MM 2007 66 100 Yes WHOc 26 15 47 12 Yes No
Nakajima T 2016 35 100 No No 0 0 35 0 NR No
Xiong ZF 2017 163 100 Yes No 39 18 42 NA Yes No
Table 4  Histochemical mucin stains and detection purpose
Stains Purpose/specific cell-type References
Alcian blue (AB) Identification of acid and neutral mucin; goblet cells [39, 47–49, 51, 52, 55–57]
Periodic acid-Schiff (PAS) with or without diastase Identification of acid and neutral mucin [39, 47, 48, 50, 51, 56]
High iron diamine (HID) with AB Differentiating sulphomucin from sialomucin [51, 56]
Galactose oxidase-Schiff (GOS) Identification of terminal β-galactose and β-N-
acetylgalactosamine; gastric surface mucous cells
[56, 58]
Periodic acid-sodium borohydride-potassium 
hydroxide (PA-SB-PH)
Identification of sialic acid O-acylated side chain; goblet cells 
in large intestine
[56]
Mucicarmine Acid mucin; goblet cells [47, 48]
Paradoxical Concanavlin A stain (PCS) Detection of stable class III mucin; cardiac glands, mucous 
neck cells, pyloric glands, and Brunner’s glands
[56, 58]
LNAase Marker enzyme for small intestine and intestinal metaplasia [55]
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Frequency of histochemical mucin positivity in gastric 
signet‑ring cell cancers
Fujiyoshi et  al. [43] categorised SRCs into ‘classical’ 
(33.3%) and ‘non-classical’ based on AB positivity, whereas 
Bakkelund et al. [44] used PAS positivity as defining feature 
of SRCs, although the amount of PAS positive material var-
ied between SRCs in the same GC and between GCs. Work 
by Terada et al. [41, 42] suggested that SRCs were positive 
for PAS-D, AB and mucicarmine, whereas Santini et al. [45] 
showed that 51% of SRC-GCs were positive for PAS, AB, 
and high-iron diamine (HID), 12% positive for AB or PAS 
and HID, and 37% showed PAS positivity only. Takenoshita 
et al. [57] compared PAS and AB positivity between ‘pure’ 
SRC-GC and tubular or poorly differentiated GC contain-
ing SRCs. All pure SRC-GC were strongly PAS positive 
and 71% were also strongly AB positive. Interestingly, the 
AB and PAS positivity rate was similar in SRC containing 
tubular or poorly differentiated GCs, and only the expres-
sion intensity was found to be lower. Furthermore, SRC-GC 
seemed to have stronger AB expression compared to PAS 
expression (p < 0.01) [57].
In summary, the frequency of AB positive SRC-GC var-
ied from 56% [45] to 64% [58], and PAS positivity varied 
from 61% [57] to 95% [45]. One study described HID posi-
tivity in 63% of GCs [45].
Relationship of histochemical mucin positivity 
with clinicopathological variables
We did not find any study investigating the relationship 
between AB and/or PAS positivity and clinicopathological 
variables or patient outcome.
A single study combined histochemical mucin stains 
(PCS, GOS, and sialidase GOS) and immunohistochemical 
stains [pepsinogen II, SH-9 (surface mucous cell stain), and 
TKH-2 (goblet cells and parietal cell stain)] to define the 
phenotype of 203 SRC-GC as gastric [> 90% surface mucous 
cell type or pyloric gland cell type, n = 130 (64%)], intesti-
nal [> 90% goblet cell type or microcyst type, n = 4 (2%)], 
or mixed gastrointestinal [10–90% gastric and/or intestinal 
cell types, n = 69 (34%)] [46]. The proportion of gastric phe-
notype SRC-GC decreased with increasing depth of inva-
sion, whereas the proportion of mixed phenotype SRC-GC 
increased with depth of invasion. This could suggest that the 
progression of SRC-GC may be associated with a pheno-
typic shift from gastric to intestinal-type mucin expression.
Immunohistochemical stains for mucin expression 
of gastric signet‑ring cell cancers
Twenty-six studies using immunohistochemistry were pub-
lished between 1997 and 2017, and the median (range) 
number of SRC-GC was 31 (12–317). The results are sum-
marised in Tables 2 and 3.
We noted a wide variation of cut-off values used to 
classify a cancer as being positive for a particular marker 
which most likely explains the wide range in reported 
positivity frequencies. MUC4, STn, and trefoil factor fam-
ily peptide (TFF) 1 and TFF3 were only investigated in a 
single study and reported to be positive in 57% [58], 57% 
to 71% [59], 33.3% and 100% [60] SRC-GC, respectively.
The frequency of single mucin stain positive SRC-GC 
ranged from 13% [41] to 95% [51] for MUC2, 11% [51] to 
100% [35, 49, 61] for MUC5AC, 29% [58] to 71% [62] for 
MUC6 and 6% [63] to 97% [63] for EMA/MUC1. A single 
study by Kim et al. [50] compared the frequency of mucin 
expression between pure SRC-GC and SRC-GC combined 
with < 50% tubular or papillary component and did not 
find any differences for MUC2, MUC5AC, or MUC6.
Some studies suggested a relationship between mucin 
expression and depth of invasion. MUC5AC expression 
was seen in tumour cells in the superficial [33, 35, 49] 
part of the gastric wall, whereas tumour cells positive for 
MUC6 [35] or PCS III [33] were more frequently found in 
deeper parts of the wall. The location of MUC2 positive 
tumour cells appeared to be more variable and could be 
superficially [49], central/marginal [35], or in a mosaic 
pattern [33].
Several studies [33–40] investigated combinations 
of mucin stains in SRC-GC (see Table 3) and described 
four SRC-GC phenotypes: gastric (G), intestinal (I), 
gastrointestinal/mixed (GI), and unclassified (UC). The 
G-type showed expression of one or more gastric mucin 
stains (MUC5AC and/or MUC6 and/or PCSIII and/or 
M-GGMC-1) and absence of intestinal-type mucin stain 
MUC2; the I-type showed expression of intestinal mucin 
stains and absence of gastric mucin stains; the GI-type 
showed a combination of stains and the unclassified type 
is negative for any mucin stains (for details, see Online 
Resource 3). However, the reported frequency of these 
phenotypes in SRC-GC varied: G-type ranged from 0% 
[39] to 81% [37], I-type from 0% [34, 35, 39] to 18% [40], 
and GI-type 0% [34] to 69% [33]. Aihara et al. [36] found 
a difference in mucin phenotype when comparing SRC-GC 
with non-SRC-GC (SRC-GC: 41 G-type, 28 GI-type; non-
SRC-GC: 20 G-type, 31 GI-type, p = 0.029).
Seki et  al. [64] divided 35 intramucosal SRC-GC 
in three groups based on the type of ILS (as described 
by Akamatsu et  al. [54]): complete type only (group 
A—40%), both complete and incomplete type (group 
B—49%), and incomplete type only (group C—11%). 
MUC2 expression was different (29%, 76%, and 100% of 
GC in groups A, B, and C, respectively. p = 0.0006).
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Relationship between immunohistochemical mucin 
stains and clinicopathological variables including patient 
outcome
Some studies reported a poorer outcome for patients with 
MUC1 positive SRC-GC [48, 60]. GI and I-type SRC-GC 
were associated with poorer overall outcome compared to 
G and UC-type (31.82% vs. 68.75%, p = 0.0146) [38]. No 
association was found between patient outcome and MUC2 
or STn positivity [60].
MUC2 positive or GI-type SRC-GC was associated with 
larger tumour diameter [35, 36, 38], increased depth of 
invasion [35, 36, 38, 40], presence of lymph-node metasta-
ses [38], or lymphovascular invasion [36, 38, 40]. Patients 
with G-type SRC-GC had smaller tumours, lower rates of 
lymph-node metastasis, or vascular invasion compared to 
other phenotypes (both p < 0.01) [38]. Furthermore, Xiong 
et al. [40] found that MUC5AC expression was inversely 
associated with depth of invasion. Bamba et al. [33] showed 
that mucosal tumour size was related to abundance of I-type 
tumour cells, whereas no such relationship was seen for 
tumour cells in deeper parts of the wall.
To the best of our knowledge, the relationship between 
mucin positivity and response to therapy has not been 
investigated.
Comparison of immunohistochemical mucin stains 
between gastric signet‑ring cell cancer and other 
histological tumour types
The relationship between immunohistochemical mucin 
expression and histological tumour type in GC is still con-
troversial. Some studies reported that tubular/papillary/
glandular adenocarcinomas were more frequently MUC1 
[47, 48, 59, 61, 62], MUC2 [47, 48] and/or MUC5AC 
[51] positive compared to SRC-GC. Whereas other studies 
found that SRC-GC were more often MUC2 [51, 59, 60, 
65], TFF3 [60], or MUC5AC [61, 65] positive compared to 
other types of GC, Ilhan et al. [51] found no relationship of 
MUC1 expression and histological tumour type. Zhang [62] 
did not find an association between MUC2, MUC5AC, and 
MUC6 expression and histological tumour type, whereas 
other studies showed that MUC2 expression was associated 
with mucinous cancers [51, 61, 62].
In conclusion, the existing number of studies on 
(immuno)histochemical mucin expression in SRC-GC is 
limited, and results are controversial most likely related to 
sample size, the use of different mucin stains, or combina-
tions of stains and variable cut-offs. We noted differences 
in frequencies of mucin positivity in SRC-GCs as well as 
differences in the reported association with clinicopatho-
logical variables including patient outcome. The majority of 
published studies were performed using material from Asian 
GC patients; thus, it is not clear whether results in Caucasian 
patients would be similar.
All the above motivated us to complement the com-
prehensive literature review with a large cohort study on 
more than 1000 patients with gastric or gastro-oesophageal 
cancers.
Results from our own gastric 
and gastro‑oesophageal cancer cohort study
This study included material from 958 (76%) patients with 
GC and 303 (24%) patients with junctional/lower oesopha-
geal adenocarcinoma. For clinicopathological and demo-
graphic cohort characteristics, see Table 1. This cohort 
included 851 Caucasian patients (LTHT cohort: 709 gastric 
and 142 junctional/lower oesophageal cancer) and 410 Asian 
patients (KCCH cohort: 249 gastric and 161 junctional/
lower oesophageal cancer).
Frequency of mucin positivity
Using the presence of expression in more than 10% tumour 
cells as cut-off for all 3 stains (MUC2, MUC5AC, AB/PAS), 
670 (53%) cancers were classified as ‘triple negative’. 172 
(14%) cancers were classified as MUC2 positive, 383 (31%) 
MUC5AC positive, and 253 (20%) AB and/or PAS positive 
(see Table 1). 145 AB and/or PAS positive cancers showed 
a mixed expression with both, the same and different cells 
being positive for AB and/or PAS. 330 (26%) cancers were 
positive for only one of the three mucin stains (48 (4%) only 
MUC2 positive, 217 (17%) only MUC5AC positive, and 65 
(5%) only ABPAS positive). 176 (14%) cancers were posi-
tive for two mucin stains whereby combined positivity of 
MUC5AC and ABPAS was most frequently seen (94 (8%) 
cancers). 42 (3%) cancers were triple positive (see also 
Online Resource 2).
Histological phenotypes and associations with mucin stains
259 (21%) cancers were classified as poorly cohesive, 943 
(75%) as non-poorly cohesive, and 41 (3%) as mucinous. 
An overview of results from the non-poorly cohesive and 
mucinous cancers can be found in Table 1 and Fig. 2. In the 
group of poorly cohesive cancers, 192 (74%), 36 (14%), 21 
(8%), and 10 (4%) cancers contained < 10% SRCs, ≥ 10–50% 
SRCs, ≥ 50–90% SRCs, and ≥ 90% SRCs, respectively. Sig-
net-ring cells were seen in mucinous cancers: < 10% SRCs 
(n = 14, 34%), ≥ 10–50% SRCs (n = 12, 29%), ≥ 50–90% 
SRCs (n = 9, 22%), and ≥ 90% SRCs (n = 6, 15%). As 
expected, the number of non-poorly cohesive cancers with 
cells looking like signet-ring cells was very low, only 38 
(3.8%) cancers contained more than 10% lookalike SRCs, 
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and none of the non-poorly cohesive cancers contained more 
than 50% lookalike SRCs.
Because of relatively small number of cases in subgroups, 
we compared poorly cohesive cancer with < 10% SRCs 
(n = 192, 15%), poorly cohesive cancer with ≥ 10% SRCs 
(n = 67, 5%), non-poorly cohesive cancer with < 10% SRCs 
(n = 905, 72%), non-poorly cohesive cancer with ≥ 10% 
SRCs (n = 38, 3%), mucinous cancer with < 10% SRCs 
(n = 14, 1%), and mucinous cancer with ≥ 10% SRCs (n = 27, 
2%) (see also Table 1).
Both, poorly cohesive and non-poorly cohesive cancers 
with ≥ 10% SRCs, were more frequently MUC2, MUC5AC, 
or ABPAS positive compared to cancers with < 10% SRCs 
(see Fig. 2). MUC2 was highly expressed in all mucinous 
cancers irrespective of the percentage of SRCs. Mucinous 
cancers with < 10% SRCs were less often ABPAS positive 
compared to mucinous cancers with ≥ 10% SRCs.
Comparison between the LTHT cohort and the KCCH cohort
The proportion of cancers with a particular histomorpholog-
ical phenotype was similar in the LTHT and KCCH cohorts 
(see Online Resource 4). In both cohorts, non-poorly cohe-
sive cancers were the most common histological subtype 
[LTHT n = 608 (71%); KCCH n = 297 (72%)]. MUC2- and 
MUC5AC-positive cancers were more frequent in the LTHT 
cohort (MUC2 LTHT n = 129 (15%) vs. KCCH n = 44 (11%), 
p = 0.043; MUC5AC LTHT n = 289 (34%) vs. KCCH n = 98 
(24%), p < 0.001), whereas ABPAS-positive cancers were 
more frequent in the KCCH cohort (KCCH n = 96 (23%) vs. 
LTHT n = 159 (19%); p = 0.037) (see also Table 1).
AB positivity was associated with worse 5-year survival 
only in the LTHT cohort (p = 0.002) (see Fig. 3). PAS, 
MUC2, or MUC5AC positivity was not related to outcome 
in any of the cohorts. Presence of combined ABPAS positiv-
ity, MUC2 positivity, and MUC5AC negativity (n = 35, 4%) 
was related to poorer 5-year survival in the LTHT cohort 
(p = 0.002) (see Fig. 3 and Online Resource 5). No other 
associations with patient outcome were found in either 
cohort.
Discussion
There is an on-going debate whether patients with signet-
ring cell (SRC) type gastric or gastro-oesophageal cancer 
have a different prognosis and response to chemotherapy 
[12–18] and, therefore, should be treated differently to 
patients with other gastric cancer (GC) subtypes. The incon-
sistent results reported in the literature could be related to 
the fact that the histopathological classification of SRC-GC 
can be challenging. This is due to the variable morphological 
appearances of individual SRCs [54–56] which may or may 
not be recognised as SRCs by some investigators [54, 54], 
as well as changing criteria in the WHO classification over 
the last decades [27–31]. Whilst an expert panel recently 
Fig. 2  Mucin expression in association with histological tumour 
type. a MUC2; b MUC5AC; c ABPAS. For PC and non-PC cases 
with ≥ 10%, RCs showed more MUC2 (p < 0.001 and p = 0.003), 
MUC5AC (p = 0.004 and p < 0.001), and ABPAS (p < 0.001 and 
p < 0.001) positivity compared to cases with < 10% SRCs. MC 
showed high MUC2 expression. MC with ≥ 10% SRCs were more 
often ABPAS positive compared to MC with < 10% SRCs (p = 0.003). 
PC poorly cohesive cancer; non-PC non-poorly cohesive cancer; MC 
mucinous cancer; SRC signet-ring cell
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proposed cut-offs to enable separating pure SRC-GC (≥ 90% 
SRCs) from GC with an SRC component, a biomarker to 
unequivocal identify SRC-GC would be of potential great 
value to clinicians and patients.
In search of a potential promising biomarker, we decided 
to focus on mucin-related stains as mucin appeared to be a 
defining characteristic of SRCs. Our group was the first to 
conduct a comprehensive literature review into the reported 
frequency and clinical importance of different mucin stains 
in SRC-GC. To our surprise, the number of studies describ-
ing (immuno)histochemical mucin expression in SRC-GC 
was very limited and results varied between studies making 
firm conclusions difficult. However, the existing literature 
seemed to suggest that mucin is not only present in SRC-GC, 
but can also be seen in other types of GC [47, 51, 59, 61, 62]. 
Furthermore, some SRC-GC appeared to contain no mucin 
[34, 35, 39]. Similarly to the well described morphological 
heterogeneity of GC, we found evidence that combinations 
of different kinds of mucins can be seen in the same GC [33, 
35–40, 45]. Our literature review supports the previous sug-
gestion of an expert panel that inconsistent clinicopathologi-
cal findings can at least partly be explained by differences 
in the histological haematoxylin–eosin-based classification 
of SRC-GC together with different cut-off values used for 
considering a stain positive. Furthermore, even if the same 
cut-off value was used, results remained contradictory [39, 
40, 48, 49, 52, 62, 63] which could be related to the use of 
different primary antibodies [64]. When comparing reported 
results from Asian and Caucasian SRC-GC [34, 39, 41, 49, 
58, 62], we saw similar wide ranges of mucin positivity, sug-
gesting that differences might not be simply related to eth-
nic origin of the cancers. Sampling of the tumours (luminal 
versus centre versus invasive front) could potentially explain 
different results in mucin expression as it has been reported 
by several investigators that intramucosal SRC-GC showed 
a ‘layered structure’ both morphologically and (immuno) 
histochemically [33, 35, 49]. Mucin characteristics of SRC-
GC varied depending on tumour size and disease stage [46, 
66], thus results might vary depending on the case selection 
for the study [35, 36, 38, 46].
In order to close the gap in the current literature 
revealed by our comprehensive review, we decided to 
conduct our own gastric and gastro-oesophageal cohort 
study into mucin stains. Our study is the largest study to 
date where all cancers were re-classified in a standard-
ised manner according to WHO classification and recent 
consensus [25]. Furthermore, our study is the first study 
to include both, Asian and Caucasian patients, enabling 
us to directly compare patient characteristics, histologi-
cal tumour types, mucin expression, and relationship 
between mucin expression and patient outcome. Previous 
studies had either investigated Caucasian cohorts or Asian 
cohorts.
Our study provides further evidence that there is no 
(immuno)histochemical mucin stain unique to SRC cancer, 
since (1) a proportion of SRC containing GC was negative 
for the (immuno)histochemical mucin stains and (2) a rela-
tively large percentage of GC without SRCs were positive 
for one or more mucin stains, similarly to what had been 
reported in the literature [47, 48, 51, 59–62, 65]. However, 
this is the first study to suggest that the mucin expression 
might be related to the quantity of SRCs within a given 
tumour as we saw more frequently mucin expression in 
poorly cohesive GC containing ≥ 10% SRCs.
When directly comparing Caucasian (LTHT) and Asian 
(KCCH) GC cohorts, MUC2 and MUC5AC positivity was 
more frequent in the LTHT cases, whereas ABPAS positivity 
was more frequent in the KCCH cases. This is the first study 
to report a relationship between AB positivity and outcome 
in GC patients. Most interestingly, AB positivity alone or in 
combination with other mucin expressions was only related 
to poor outcome in Caucasian GC providing further support 
for the hypothesis that different outcome in Caucasian and 
Asian GC patients may be related to an underlying biological 
difference [67]. As AB stains acidic mucins which are con-
sidered to be present in an intestinal phenotype, our finding 
would support the described association between (gastro) 
intestinal mucin phenotype and unfavourable outcome [38]. 
Due to relatively low patient numbers in mucin-defined sub-
groups, we were unable to explore whether the AB expres-
sion related outcome difference between cohorts was related 
to a different disease stage mix.
Based on the literature review and the results of our 
cohort study, we had to reject our first working hypothesis 
and conclude that SRC containing GC do not have a differ-
ent mucin expression compared to non-SRC-GC. Further 
studies are needed to address this clinical need. On the 
other hand, results reported in the literature and from our 
own cohort study confirmed a relationship between SRC 
mucin expression and patient outcome in the surgery alone 
setting. Furthermore, our cohort study suggests that irre-
spective of histological phenotype, the mucin expression is 
different in Caucasian and Asian GC patient and is associ-
ated differently with outcome in different ethnic groups.
We recommend further studies comparing Cauca-
sian with Asian GC to validate our findings and explore 
underlying molecular mechanisms for difference in mucin 
expression and outcome. Also, we recommend investigat-
ing whether the different mucin expression in SRC con-
taining GC is related to variable treatment response.
776 K. G. P. Kerckhoffs et al.
1 3
Fig. 3  Kaplan–Meier plots showing probability of 5-year survival 
stratified by AB expression and cohort a and b Kaplan–Meier survival 
analysis showed in the LTHT cohort significantly worse outcome in 
AB positive GC (p = 0.002), this was not seen in the KCCH cohort. c 
Example of CK-ABPAS stain showing positivity for AB (blue stain-
ing). d Example of CK-ABPAS stain showing positivity for PAS and 
combined AB-PAS positivity (pink and purple staining respectively)
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